Seattle Genetics, Inc. (NASDAQ:SGEN) Files An 8-K Results of Operations and Financial ConditionItem 2.02
On July27, 2017, Seattle Genetics, Inc. issued a press release announcing financial results for its second quarter ended June30, 2017. A copy of the press release is furnished herewith as Exhibit99.1.
The information furnished with this report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.
| Item 2.02 | Financial Statements and Exhibits. |
| 99.1 | Press Release of Seattle Genetics, Inc. dated July27, 2017 |
SEATTLE GENETICS INC /WA ExhibitEX-99.1 2 d428106dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Seattle Genetics Reports Second Quarter 2017 Financial Results -Second Quarter 2017 Revenues Were $108.2 Million,…To view the full exhibit click here
About Seattle Genetics, Inc. (NASDAQ:SGEN)
Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company’s product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC), comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE). The Company’s pipeline includes other clinical-stage ADC programs, which are SGN-CD33A, SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology. SGN-CD33A is an ADC composed of an anti-CD33 monoclonal antibody indicated for the treatment of acute myeloid leukemia (AML). SGN-CD19A is an ADC composed of an anti-CD19 monoclonal antibody indicated for the treatment of hematologic malignancies. SGN-LIV1A is an ADC composed of an anti-LIV-1 monoclonal antibody indicated for the treatment of LIV-1-positive metastatic breast cancer.
